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ABSTRACT
This unit describes the use of quantum dots (QDs) for live-cell imaging and the use of
QDs in flow cytometry for quantitative analysis of ligand binding constants and receptor
density. Conventional fluorophores and visible fluorescent protein (VFP) constructs have
allowed visualization of many cellular processes. However, organic and biomolecular
fluorophores have limitations in their applications, due to their small Stokes’ shift and
tendency to photobleach during prolonged imaging. QDs have many advantages over
conventional fluorophores, including high brightness and photostability, which make
them an exceptional tool for live-cell imaging. There are a large variety of commercially
available QDs with different surface reactivities and characteristics. The authors have
limited the laboratory protocols presented here to the use of streptavidin-coupled QDs
because this gives almost universal applicability to any cell surface receptor by coupling
the ligand or antibody that recognizes the receptor to biotin and visualizing the complex
by use of QDs. Curr. Protoc. Cell Biol. 36:25.1.1-25.1.18. C© 2007 by John Wiley &
Sons, Inc.
Keywords: quantum dots  live-cell imaging  binding constants  receptor number 
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INTRODUCTION
The responses of a cell to its surrounding environment result largely from the transduction
of signals from the outer cell surface to the cytoplasm and nucleus. These signals are
initiated when a ligand binds to a membrane receptor, initiating signaling cascades
that control numerous cellular processes such as gene expression, cell migration, and
cell division. Macromolecular protein dynamics and localization, as well as signaling
cascades, can be directly visualized in the living cell using fluorescence microscopy [see
other units on FRAP (UNIT 21.1), ion imaging, and fluorescent imaging (Chapters 4 and
21)].
In this unit, the authors describe protocols for forming biotin-ligand (or biotinylated-
‘protein of interest’) and streptavidin-QD (SAvQD) complexes for use in live-cell mi-
croscopy (see Support Protocol 1). In the case when the precoupling of the QD to the
ligand inhibits function, an alternative two-step labeling protocol is provided. Support
Protocol 2 discusses ways to avoid cross-linking of QD-ligand complexes if the ligand is
labeled with multiple biotins. Basic Protocol 1 gives details for in vivo cell labeling with
QD-ligand complexes and image acquisition, with special emphasis on temporal acquisi-
tion of image series to visualize cellular processes. Experiments to determine QD-ligand
binding constants (Basic Protocol 2) and absolute number of receptors per cell (Basic
Protocol 3) by complementary flow cytometry measurements are also described.
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STRATEGIC PLANNING
What are quantum dots and how are they useful for live-cell imaging?
Water-soluble, bio-functionalized semiconductor quantum dots (QDs) are fluorescent
nanoparticles that provide advantages of much greater photostability compared to con-
ventional fluorescent dyes, and as a consequence, single QDs can be easily detected in
living cells and their localization monitored for minutes to hours to days. The core of the
QD consists of a semiconductor nanocrystal, typically CdSe surrounded by a passivation
shell of ZnS, as well as an outer shell to make them biocompatible (Alivisatos et al., 2005;
Smith et al., 2006). Absorption of a photon anywhere in a continuum rising toward the
UV generates an electron-hole pair, which upon recombination (in ∼10 to 20 nsec) results
in the emission of a less energetic photon. The emission wavelength is dependent on the
size of the core (smaller core size = lower emission wavelength), which can be varied by
controlled synthesis conditions (Fig. 25.1.1). These characteristics and the fact that QDs
have a large absorption cross-section, particularly in low visible to UV wavelengths, al-
lows for the simultaneous excitation of many spectrally distinct QD emitters with a single
wavelength. (See later section on multispectral fluorescence imaging and analysis).
Many types of QDs are commercially available from Invitrogen (http://probes.
invitrogen.com/products/qdot) and Evident Technologies (http://www.evidenttech.com).
These include surface-accessible moieties such as amino, carboxyl, peptides, biotin,
streptavidin, protein A, and IgGs. The manufacturers provide kits for coupling your fa-
vorite molecule to QDs with extensive protocols and the reader is referred to these sites
for details. In addition, membrane-permeable QDs (having nona-arginine on the surface)
and other methods of intracellular delivery are available so that QDs may be used to label
cells for reintroduction into animals and long-term cell tracking. The larger CdSe QDs,
emitting at >600 nm, have extended geometries with dimensions of ∼40 nm. These large
sizes make accessibility a problem in tight junctions between cells or in permeabilized
tissues (Arndt-Jovin et al., 2006). Emission wavelengths of QDs have been extended
into the near NIR using CdTe as cores (Kim et al., 2004; Gao et al., 2005; Smith et al.,
2006), thus enhancing their use in live-animal studies. An exciting in vivo quantum dot
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conjugate that emits by bioluminescence resonance energy transfer in the absence of
external excitation has been prepared by coupling carboxylate-presenting quantum dots
to a mutant of the bioluminescent protein Renilla reniformis luciferase (So et al., 2006).
Differences between QDs as probes and small or conventional fluorophores
Most conventional fluorophores have relatively broad absorption and emission bands
with a small to medium Stokes’ shift (the difference in wavelength between their excita-
tion and emission maxima). For information on the excitation and emission maxima for
many small molecule fluorophores see http://probes.invitrogen.com/handbook. Geneti-
cally encoded fluorophores (VFPs, visible fluorescent proteins) have small Stokes’ shifts
except for the recently described Keima (Chudakov et al., 2005; Shaner et al., 2005;
Kogure et al., 2006). Thus, it is more difficult to excite several conventional fluorophores
with a single wavelength. For excitations in the visible wavelengths many conventional
fluorophores have higher extinction coefficients than QDs and with their shorter fluores-
cent lifetimes will appear ‘brighter’ to the observer. However, these dyes are much less
photostable than QDs. This latter fact makes QDs the probe of choice for in vivo imaging
over extended time periods.
Instrumentation
Microscopy
Macromolecular dynamics, localization, and aggregation state can be directly visualized
in the living cell using fluorescence microscopy [see units on basic fluorescence mi-
croscopy (UNIT 4.2), FRAP (UNIT 21.1), FRET (UNITS 17.1 & 17.9) and fluorescence correlation
spectroscopy (FCS)]. Commercial confocal microscopes allow for multi-laser excita-
tion and the imaging of several different fluorophores simultaneously. Recent advances
in multispectral fluorescence imaging, where the emission spectrum of the sample is
measured in each sampled point, have made it possible to further increase the number of
fluorophores that can be monitored (Fountaine et al., 2006). Commercial systems include
the Zeiss LSM 510META and Live systems, Nikon Digital Eclipse C1si, Leica TCS SP5,
Olympus Fluoview, and Olympus DSU spinning disk. QDs are particularly suited to si-
multaneous multi-color labeling of different macromolecules in the same sample due
to their broad excitation spectra and narrow emission spectra, which allows for single
line excitation of multiple QDs and separation of spectrally distinct QD emissions using
filter-based or multispectral imaging.
In addition to confocal imaging, high spatial and time resolution can be achieved using
a wide-field microscope and a sensitive CCD camera (see UNIT 4.2). The brightness and
photostability of QDs make it possible to track individual protein dynamics in living cells
at video rate or faster using the new generation electron multiplying (em) CCD cameras
(Andor iXon, Roper Scientific Cascade, Hamamatsu C9100-02). The high quantum
efficiency of CCD cameras extending into the NIR makes them far superior for detecting
QDs with emissions >600 nm compared with PMT-based imaging systems.
Flow cytometry
Flow cytometry is a complementary technique to imaging microscopy. The authors in-
clude a discussion of it here to demonstrate its power for quantitative determination of
binding constants, numbers of binding sites, as well as kinetic or dissociation constants
with high statistical precision. Flow cytometry has both advantages and disadvantages
compared to microscopy. It can record the fluorescence and light scattering of hundreds
or thousands of cells in a second, but speed comes at the price of losing subcellu-
lar resolution. Although some flow cytometers are capable of multi-laser excitation,
in the simplest and probably most wide-spread bench-top flow cytometers the num-
ber of excitation wavelengths is limited. Similarly as in the imaging microscope, the
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multi-color labeling possible and easily detected in different fluorescence channels of
the flow cytometer (Mattheakis et al., 2004; Chattopadhyay et al., 2006). The photosta-
bility of QDs is less valuable in flow cytometry due to the limited amount of time the
cells are illuminated, but their relatively large extinction coefficient (especially with UV
excitation) makes the labeling of cells with low numbers of binding sites more reliable.
BASIC
PROTOCOL 1
IN VIVO, IN SITU LABELING OF CELLS WITH QD-LIGAND CONJUGATES
FOR FLUORESCENCE MICROSCOPIC IMAGING
This method describes the general procedure for preparing cells for live imaging in
order to follow the fate of the QD-ligands interacting with membrane-bound receptors
(see Fig. 25.1.2). The methods can be used with a confocal laser scanning microscope
or a wide-field microscope. The use of LabTek chambers (Nunc) requires the use of
an inverted microscope. Other manufacturers such as Electron Microscopy Services
(http://www.emsdiasum.com/microscopy/products/preparation/dish.aspx) make holders
that accommodate coverslips of various dimensions that are equally suitable. With live-
cell imaging, dynamic events (i.e., QD-ligand binding/internalization or endosomal traf-
ficking) can be monitored by acquiring an image series over the time range of interest.
If quantitative analysis of data is desired care must be taken to acquire the images such
that no pixels have intensities of 0 or less nor values above the range of the detector
(8-bit, 12-bit, or 16-bit for example.)
Controls for the specificity of the QD-receptor interaction are important. It is absolutely
essential to show that the signal that is acquired is specifically associated with the
presumed receptor and that it reflects the behavior of the receptor without QDs attached.
The researcher must do binding experiments with unconjugated QDs, and QD-ligand
binding in the presence of competitive excess free ligand, determine if down-stream
signaling is affected as expected (e.g. phosphorylation profiles are the same with QD-
ligand compared with ligand alone), and demonstrate that there is no binding on cells
that do not express the receptor.
If one wishes to perform single-particle tracking of individual receptors, it may be
desirable to use the QD simply as a tracer of the molecule of interest. This may be done
Figure 25.1.2 QD-EGF (red) bind to the surface of Chinese hamster ovary cells expressing
EGFR-GFP (green) (A) and undergo endocytosis within minutes (B). Colocalization (yellow) of
the QDs and receptor are seen at the membrane and after internalization in endosomes. Images
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by using a very low concentration of QD-ligand mixed with an excess of free ligand
(Lidke et al., 2005a) or by binding the biotinylated-ligand (Alternate Protocol) followed
by a tracer amount of SAvQDs (Echarte et al., 2007).
Materials
Logarithmically growing cells (UNIT 1.1)
Trypsin
Cell culture medium appropriate for the particular cell line
Tyrode’s buffer plus (see recipe)
Preformed QD-ligands (Support Protocol 1 or 2)
LabTek 8-well coverslip chambers (Nunc)
Emission filters for specific QD emission wavelengths (Chroma or Omega, also
available from the microscope manufacturers)
Additional reagents and equipment for culture of cells (UNIT 1.1)
Plate cells
1. One or two days before the experiment, trypsinize logarithmically growing cells
(UNIT 1.1).
2. Plate the cells in LabTek 8-well coverslip chambers in complete culture medium at
the appropriate density (one typically desires ∼50% confluency on the day of the
experiment).
In the case of experiments with receptors that are sensitive to serum factors, the cells can
be serum-starved for 4 to 16 hr prior to the experiment to reduce signaling induced by
the serum in the medium.
Prepare sample for live-cell imaging with QD-ligand complexes
3. At the time of the experiment, wash the cells once with 200 µl Tyrode’s buffer plus
and maintain in this buffer.
Culture medium without phenol red, containing 1% (w/v) BSA can be used for very long
imaging periods (in place of Tyrode’s buffer plus).
4. Place the chamber on the microscope stage and equilibrate to the desired temperature.
The authors recommend an objective heating collar as the most effective way to keep the
cells at the desired temperature during the duration of the experiment. An inexpensive and
efficient setup can be purchased from Cell MicroControls (HLS8 × 0.8P and mTCII) and
consists of an adjustable, flexible heating strip that can be secured around any objective
with a strip of Velcro and a battery powered controller. For very long (hours to days)
experiments a system having CO2 input is necessary as well.
5. Dilute the QD-ligand complex (Support Protocol 1 or 2) to twice the desired final
concentration in Tyrode’s buffer plus.
Dilute the ligand-SAvQD complex from PBS/1% BSA into Tyrode’s plus just before use
since the SAvQDs can aggregate with time in buffers containing divalent cations. Do not
store this dilution for use on another day.
6. Add an equal volume (200 µl) of QD-ligand in Tyrode’s buffer plus to the cells in
the well under observation to a final concentration of 0.005 to 2 nM.
The final concentration should be adjusted for the specific protein-ligand interaction and
the known binding constants. Also, the concentration will depend on whether one wants
to observe many or only a few of the receptors at one time (i.e., single-molecule tracking
or measuring binding and uptake). The two-step labeling procedure is recommended if
a maximal cellular response but single-molecule resolution are desired. This procedure
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Image acquisition
7. Initiate image acquisition either before or just after addition of the QD-ligand.
That is, when using preformed complexes, the QD-ligand can be added to the sample
after images at several time points have already been acquired, taking care not to disturb
the position of the sample during addition of the QD-ligand. Typically, addition of large
volumes (e.g., addition of 200 µl of QD-ligand to 200 µl of buffer in chamber) results in
rapid mixing without additional pipetting. The QD-ligand should also be kept at the same
temperature as the imaging chamber to avoid focal drift due to temperature fluctuations.
The time between images and duration of the time series acquisition is dependent on the
events being monitored and must be determined by the researcher.
A 63× or 40× 1.2 NA water immersion objective is recommended.
In confocal imaging systems, simultaneous excitation of VFP and various QDs can be
achieved by using different laser combinations. QDs having emissions of 605 nm and
above can be excited well by 488 nm or higher wavelengths whereas lower wavelength
QDs are more efficiently excited by 458-nm or 407-nm lasers. An imaging system with at
least two detectors, allows the simultaneous collection of eGFP and QD signals with ap-
propriate filters (eg., 520/20 bandpass and the appropriate QD emission bandpass filters).
Single QD imaging requires high laser powers and pixel dwell times of about 6µsec. Thus,
whole 512 × 512 image acquisitions take seconds. Fast-tracking of single QDs requires
more sensitive acquisition systems (see next section). For the most efficient separation of
different emitting QDs in the same sample, selective QD emission filters or a spectral un-
mixing device should be used (Fountaine et al., 2006; Miskoski et al., 2006; see Fig 25.1.3).
Wide-field systems equipped with a mercury arc lamp most efficiently excite the QDs at 436
nm without cell damage. Image splitters and multispectral analysis systems can separate
many QD and VFP labels simultaneously (Miskoski et al., 2006). EmCCD cameras can
easily detect QD emission from single bound QDs with acquisition times of 50 ms or less
(see Fig. 25.1.4).
Image analysis is specific to the particular question being addressed and therefore, must
be developed by the researcher. There are many commercial and noncommercial re-
sources available for image processing. Two of the most popular platforms are ImageJ, a
stand-alone software available through NIH (http://rsb.info.nih.gov/ij/) and DIPimage, a
Figure 25.1.3 In a ‘pulse-chase’ experiment, two different colors of QD-EGF (red and blue)
added to a cell expressing erbB1-eGFP (green) are used to monitor vesicle fusion. First, red
QD-EGF is added and allowed to internalize. At a time point 15 min later, the blue QD-EGF is
added. At a time point 22 min after addition of the blue QD-EGF, colocalization of red and blue QDs
are seen in endosomes (purple), indicating that receptors activated later in time can ‘catch-up’
to the same compartment as those that were internalized earlier. Image acquired using a Zeiss
LSM510-META system. For color version of this figure see http://www.currentprotocols.com.
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Figure 25.1.4 Single QD Blinking. Selected images from a time series showing the intermittent
fluorescence of an individual QD. Time series acquired using an Olympus IX71 microscope with
an Andor iXon emCCD camera. Excitation: 472-nm diode laser; emission: 655/40 QD filter. 60
msec between images, 20 msec integration time (see Lidke et al., 2005b).
scientific image processing toolbox for Matlab available from Delft University of Technol-
ogy (http://www.ph.tn.tudelft.nl/DIPlib/). These two programs are free to University staff
and students. A large number of plug-ins or scripts have been developed for both pack-
ages, such as masking operations, tracking algorithms, colocalization or 2-D histograms,
and are freely available to the public.
ALTERNATE
PROTOCOL
LABELING CELL SURFACE RECEPTORS IN A TWO-STEP PROCEDURE
In some cases, the presence of the QD may sterically hinder the QD-ligand binding to
the cell surface membrane receptor. If one does not observe binding of the preformed
complex, the following two-step protocol may be useful. The authors have successfully
used this procedure with EGF, transferrin, and NGF receptors (Grecco et al., 2004; Lidke
et al., 2004; Echarte et al., 2007).
Materials
Cells cultured in chambers or on coverslips (Basic Protocol 1)
Tyrode’s buffer plus (see recipe), cold
Bio-ligand
Streptavidin-conjugated Quantum Dots (SAvQD; Invitrogen)
4% (w/v) paraformaldehyde
Tris-saline buffer
Phosphate-buffered saline (PBS; see recipe)
10◦ to 12◦C water bath
1. Put chambers or coverslips containing cells on ice or float chamber in a water bath
maintained at 10◦ to 12◦C (recommended for cells of the immune system which are
sensitive to extreme cold).
2. Wash cells once with cold Tyrode’s plus and maintain in this buffer for the experiment.
3. Incubate cells with bio-ligand for 10 to 30 min.
The concentration of bio-ligand and incubation times should be adjusted according to
the binding constant of the protein-ligand interaction.
4. Wash with cold Tyrode’s plus several times.
5. Add 0.05 to 2 nM cold SAvQD (diluted in Tyrode’s plus) for 5 to 15 min.
6. Wash the cells several times with cold Tyrode’s plus.
7. Mount for imaging.
a. For live-cell imaging, immediately place cells on the microscope stage with ap-
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b. For snapshots of the behavior of the QD-ligand complex at different time points,
incubate cells grown on coverslips at the appropriate temperatures and times and
fix in 4% paraformaldehyde for 15 min on ice to prevent redistribution of the QDs.
After fixation, wash the coverslips with Tris-saline buffer for 10 min several times
and mount in PBS for imaging.
SUPPORT
PROTOCOL 1
COUPLING MONOBIOTINYLATED LIGANDS TO STREPTAVIDIN-QDS
This method describes how to conjugate ligands to QDs via a biotin-streptavidin inter-
action. The authors have successfully used this protocol for several biotinylated ligands,
including epidermal growth factor (EGF; Lidke et al., 2005a) and nerve growth factor
(NGF; Echarte et al., 2007).
This protocol can be used with most ligands and proteins (such as antibodies) that have
a single biotin moiety attached. The protocol uses QDs from Invitrogen that have 3 to
4 streptavidin molecules covalently bound to the QD bioconjugate shell (SAvQD). The
authors recommend for most applications the PEG 2000 coated QDs since they show
reduced nonspecific binding to cells and cell substrates such as polylysine or collagen.
The reader is reminded that each streptavidin can have up to four binding sites for
biotin. The multi-valency of the SAvQDs can be an advantage in that it allows for the
stochiometry of the QD-ligand complex to be varied by simply changing the ligand:QD
ratio. A monovalent biotinylated ligand, where the biotin is conjugated to a single known
residue or position, is preferred since the properties of the QD-ligand complex can be
better controlled and potential cross-linking of the QDs via the ligand is avoided (see
Support Protocol 2 for ligands with multiple biotins). By mixing SAvQDs, biotinylated
ligand and free biotin at specific molar ratios, one can create QDs with the desired average
number of attached ligands, assuming a Poisson distribution (Lidke et al., 2004).
After formation of the QD-ligand complex, unbound ligands that are smaller than the
QDs can be removed from the conjugate by passing the mixture over a size exclusion
column. For PEG-QDs cross-linked dextran size exclusion columns (eg, Sephadex G-25)
are recommended, and for QDs without a PEG coating, polyacrylamide bead exclusion
columns are most efficient (eg, Bio-gel P).
Materials
Streptavidin-conjugated Quantum Dots (SAvQD; Invitrogen)





Gel filtration spin columns, NAC-5
Prepare QD-ligand preformed complexes
1. Dilute SAvQD to 20 nM in 100 µl PBS/1% BSA.
2. Dilute bio-ligand to 20 to 60 nM in 100 µl PBS/1% BSA.
The above concentration will yield a Poisson distribution of 1:1 to 3:1 ligands per QD. The
reader should determine the valency of ligand desired for his/her particular experiment.
3. Add SAvQDs to ligand, mix with a micropipet, and vortex for 1 sec.
Thoroughly mix the SAvQDs and ligand in equal volumes so that the stoichiometry does
not vary throughout the solution at the time of mixing.
4. Incubate for at least 30 min at 4◦C with gentle agitation or rotation.
Nanotechnology
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Purify QD-ligand conjugates
5. Swell and pour the column material according to the manufacturer’s instructions.
For PEG-coated QDs coupled to small peptide ligands as described above, Sephadex
G-25 medium-grade gel filtration is recommended; the QD-ligand complex will elute in
the void volume. Use a 1:20 ratio of sample to column volume to ensure separation.
Spin columns can be used for sample volumes of 50 µl or less. For non-PEG SAvQDs,
Bio-gel P20 is recommended; the QDs appear in the void volume. To remove excess
macromolecules from QD conjugations, ultra filtration units with 100-kDa or 200-kDa
regenerated cellulose membranes are recommended (see Millipore Corporation for small
volume ultracel or microcon units).
6. Equilibrate the column in PBS by washing with at least 3 column volumes.
7. Allow the buffer to just enter the top of the gel bed before adding the sample. Avoid
air bubbles.
8. Add the sample to the top of the gel bed, allow the sample to enter the gel, and add
PBS to elute the sample.
9. Collect the fractions containing the QDs. Add 1% (w/v) BSA (final concentration)
to final product
The purified QD-ligand complexes are stable for 4 weeks when stored at 4◦C.
SUPPORT
PROTOCOL 2
PREPARATION OF PREFORMED COMPLEXES OF QDS WITH LIGANDS
WITH MULTIPLE BIOTINS
Some ligands must be multivalent for proper recognition by their receptors. The ligand
may thus also be multi-biotinylated. The following protocol has been successfully used
with such ligands and avoids cross-linking of QDs by the ligand by blocking excess
biotin binding sites on SAv-QDs with free biotin shortly after addition of the ligand (see
Cambi et al., 2007 for an example).
Materials
Streptavidin-conjugated Quantum Dots (SAvQD; Invitrogen)
PBS/1% (w/v) BSA (see recipe)
Bio-ligand
1. Dilute SAvQD to 20 nM in 100 µl PBS/1% BSA.
2. Dilute bio-ligand to the appropriate molarity in 100 µl PBS/1% BSA and mix with
the QDs for 15 min with agitation.
After addition of free biotin, the ligand-QD complexes can be purified as described above
(Support Protocol 1, steps 3 and 4) or used directly if the free biotin and potentially free
ligand do not interfere with receptor recognition.
The absolute concentration of the ligand should be carefully determined. The number of
biotins per ligand should also be determined.
The authors recommend adding the ligand at a concentration such that the final dilution
has a ratio of approximately three to six ligands to one QD and allowing binding to
proceed with agitation for only 15 min followed by the addition of a 10-fold excess of free
biotin to saturate any remaining streptavidin binding sites.
The success of this procedure will depend to some extent upon the nature of the ligand.
The authors assume that there are at least two available biotin binding sites for each
streptavidin. Due to the geometries of the QDs, the nature of the ligand, as well as how
the biotins are arrayed on its surface, not all biotins will be able to bind to the QD surface.
The authors have found that polymeric ligands of ∼30 to 40 kDa with approximately three
biotins per polymer show no detectable cross-linking of QDs when added to the QDs at
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BASIC
PROTOCOL 2
FLOW CYTOMETRIC DETERMINATION OF THE BINDING CONSTANTS
OF LIGANDS OR ANTIBODIES
Ligand binding to its receptor is the first step in transmembrane signaling. The easiest
way to characterize this interaction is to determine the equilibrium binding curve, i.e.,
ligand binding as a function of ligand concentration. Fluorescence has largely replaced
the use of radioactivity in such experiments. This protocol describes how fluorescent
QDs can be used for the determination of dissociation constants.
Materials
Biotin-coupled ligand or antibody
Avidin-coated QD (Invitrogen or Evident Technologies) suitable for excitation with
the flow cytometer available
Trypsin
Phosphate-buffered saline (PBS)/1% (w/v) BSA (see recipe)
Flow cytometry tube
Flow cytometer
Flow cytometric analysis software
Additional reagents and equipment for coupling the ligand or antibody of interest
to QDs (Support Protocol 1) and culture of cells (UNIT 1.1)
1. Couple the ligand or antibody of interest to QDs (see Support Protocol 1).
2. Trypsinize cells (UNIT 1.1), resuspend them in PBS/1% BSA at a concentration of
5 × 106/ml.
3. Prepare a 2-fold dilution series of QD-ligand. Add 1000 µl of the highest concentra-
tion of QD-ligand made in PBS/1% BSA to a flow cytometry tube. Prepare dilutions
starting from a concentration ∼10× higher than the anticipated Kd. Mix thoroughly.
Keep all the tubes on ice during the entire labeling procedure. Pipet 500 µl from this
solution to another tube into which 500 µl of PBS/1% BSA is added yielding the
second highest concentration. Repeat this procedure until the lowest concentration
is reached.
Be aware that in the presence of ligand concentration 9× higher than the Kd, 90% of the
binding sites will be occupied, if binding is noncooperative.
At the end of this step flow cytometry tubes will be filled with 500 µl of different concen-
trations of the QD-ligand on ice.
4. Add 20 µl of the cell suspension to each tube and incubate for 30 to 60 min on ice
with regular mixing.
The QD-ligand is diluted negligibly by the 20 µl cell suspension, since 500 µl >20 µl.
5. Measure the samples with a flow cytometer.
Keep the cells on ice until measurement. Alternatively, samples can be fixed in 1%
formaldehyde after removing unbound QD-ligand by washing twice with PBS.
Measure a nonlabeled cell sample too, the fluorescence intensity of which will be sub-
tracted from the mean fluorescence intensities of each sample. Pay attention to the fact
that all cells in the brightest and darkest samples have to be on scale, otherwise the means
will be distorted.
6. Using a flow cytometric analysis software, determine the mean fluorescence inten-
sities of each sample gated on the FSC-SSC dot plot.
7. Plot the autofluorescence-corrected mean fluorescence intensities as a function of the
total QD-ligand concentration (assumed to be equal to the free ligand concentration).
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8. Fit the following, so-called Hill equation to the measured data points:
where I is the fluorescence intensity in the presence of QD-ligand concentration of
c, Kd is the dissociation constant required to half-saturate the binding sites, and n is
the Hill coefficient characterizing the cooperativity of binding.
If there is good reason to believe that there is no cooperativity (e.g., if one ligand binds
to a monomeric receptor species), it can be assumed that n = 1, and a simpler equation
can be used:
In this case Kd has real meaning characterizing the binding event, e.g., it is equal to the
ratio of the dissociation and association rate constants. If n = 1, Kd lacks any direct
molecular implications. Indeed, the Hill coefficient itself cannot be translated into a
real molecular model, since the Hill equation is the result of a reductionist view of the
molecular events taking place during complex formation.
BASIC
PROTOCOL 3
FLOW CYTOMETRIC QUANTITATION OF THE NUMBER OF ANTIBODY
BINDING SITES
The number of binding sites for a ligand or antibody, i.e., the total number of expressed
antigens is a significant issue: for example, it has predictive value in cancer diagnosis.
Flow cytometry has obvious advantages over cell suspension-based methods (e.g., ra-
dioactive binding analysis), since it is capable of resolving heterogeneity and eliminates
the influence of dead cells and cell debris. The idea behind the calibration procedure is
to run a series of reference beads with calibrated number of antibody binding sites or
fluorescence intensities. Three approaches are widely used:
1. Beads with calibrated fluorescence intensities (e.g., Quantum FITC MESF beads from
Bangs Laboratories). The kit contains several bead populations each corresponding to
the fluorescence intensity of a calibrated number of fluorophores. The company provides
a calibration software (QuickCal) for the calculations, which can also be easily carried
out with a spreadsheet program. Different beads are available for different fluorophores.
To the best of our knowledge, no such beads are available for the calibration of QD
fluorescence intensities, therefore the authors will not provide a detailed protocol.
2. The Qifikit calibration kit (Dako) contains a series of beads coated with different,
calibrated numbers of mouse monoclonal antibody molecules. The beads have to be
labeled by the secondary antibody used for labeling of the cells. A plot of the fluorescence
intensity of the beads against the number of binding sites will be constructed.
3. The Quantum Simply Cellular kit (Bangs Laboratories) contains subpopulations of
beads with calibrated binding capacities for the Fc region of mouse or human antibod-
ies. The beads have to be labeled with a primary antibody followed by a secondary,
fluorochrome-conjugated antibody in the same way as the cells. A calibration plot of
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Secondary QD-conjugated antibody against the primary antibody (Quantum Dot
Corporation or Evident Technologies)
Phosphate-buffered saline (PBS)/1% (w/v) BSA (see recipe)
Qifikit calibration kit (Dako)
Vortex
Qifikit calibration beads (Dako-Cytomation, www.dako.com) or Quantum Simply
Cellular beads (Bangs Laboratories, www.bangslabs.com)
Flow cytometer
Quantum Simply Cellular kit (Bangs Laboratories)
For Qifikit
1a. Label the cells under investigation with saturating concentration of the primary
unlabeled antibody.
2a. After washing the cells twice with 2 ml PBS, label them with the secondary, QD-
conjugated secondary F(ab’)2. Include a cell sample which is only labeled by the
primary antibody for background correction.
Cells and beads should be labeled with secondary antibody at the same time (see step
4a).
3a. After vortexing remove 100 µl from the Setup and Calibration bead vials, centrifuge
the beads 4 min at 1400 × g, 4◦C, after adding 3 ml of PBS/1% BSA.
The Qifikit beads are coated with primary mouse antibodies, and can only be used for the
calibration of secondary antibody binding to cells labeled by primary mouse antibodies.
4a. Remove the supernatant and label the bead pellet with the secondary QD-conjugated
secondary F(ab’)2 under the same conditions as the cells.
This step should be done at the same time as step 2a.
5a. Run the cells and the two Qifikit bead samples (Setup and Calibration) on the flow
cytometer.
6a. Subtract the fluorescence intensity of the sample labeled by the primary antibody
only from the intensity of the sample labeled by both the primary and secondary
antibodies (background-corrected intensity).
7a. Analyze the fluorescence of the unlabeled bead population in the Setup sample and
the five subpopulations in the Calibration sample. Subtract the mean fluorescence
intensity of the unlabeled bead population from the fluorescence intensities of the
calibration beads. Plot the background-corrected fluorescence intensities of the cal-
ibration bead subpopulations as a function of the number of binding sites which is
included in the manual for the kit. Fit a line to the data points.
8a. Find the number of antibody binding sites on the cells based on their background-
corrected fluorescence intensity using the calibration line.
For Quantum Simply Cellular beads (secondary labeling)
1b. Combine one drop of each of the beads with graded number of binding sites for
human or mouse antibodies.
The blank bead with no capacity for antibody binding can also be combined with the
others, or can be processed separately.
The Quantum Simply Cellular beads can capture a calibrated number of mouse or human
monoclonal antibodies by their Fc domain allowing them to be used for the calibration
of both primarily or secondarily labeled cells. The authors have provided a protocol for
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2b. After mixing the beads vortex them. Label both the cells and the beads with saturating
concentration of the primary unlabeled antibody.
3b. Add 5 to 10 ml PBS, centrifuge 4 min at 1400 × g, 4◦C, and repeat washing step once
more. Label the cells and the beads with the secondary, QD-conjugated secondary
F(ab’)2. Include a cell sample which is only labeled by the primary antibody for
background correction.
4b. Add 5 to 10 ml PBS and centrifuge the samples 4 min at 1400 × g, 4◦C. Repeat the
washing step once more before running the samples on the flow cytometer.
5b. Subtract the mean fluorescence intensity of the blank bead population from the
fluorescence intensities of the labeled beads. Plot the background-corrected fluores-
cence intensities of the calibration bead subpopulations as a function of the number
of binding sites. Fit a line to the data points.
6b. Find the number of antibody binding sites on the cells based on their background-
corrected fluorescence intensity using the calibration line.
The company provides an online program, QuickCal (www.bangslabs.com/flow/quickcal),
which can perform the above calculations automatically.
REAGENTS AND SOLUTIONS
Use deionized, distilled water in all recipes and protocol steps. For common stock
solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
Paraformaldehyde (PFA) fixative
Prepare a fresh 4% (w/v) solution of paraformaldehyde, analytical grade in PBS
(see recipe). Use only for 1 day, keep on ice.
A 40% solution can be prepared and kept in small aliquots at −20◦C. Thaw at 50◦C and






Adjust pH to 7.3 using NaOH or HCl, if necessary
Autoclave
Store up to 6 months at room temperature
PBS/1% (w/v) BSA







Adjust pH to 7.2 using NaOH
Autoclave
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Tyrode’s buffer plus




Published results of in-vivo QD imaging
QD are not “brighter” than conventional
fluorophores since they have relatively long
fluorescence emission lifetimes. Also, due to
their large size (dictated by the necessity of
several layers of material for passivation and
biocompatibility beyond the emitting core),
there may be steric hindrance to binding com-
pared to small fluorophores in applications
such as in situ hybridization or labeling to ar-
rays like cytoskeletal components. They are
most important for their extreme photostabil-
ity and thus have been used most effectively
as labels for in vivo imaging. In particular,
their application to the study of the behav-
ior of cell surface receptors has brought new
insights at single-molecule resolution (Dahan
et al., 2003; Lidke et al., 2005a; Arndt-Jovin
et al., 2006; Courty et al., 2006; Echarte et al.,
2007; Hagen et al., 2007). An area beyond the
scope of these protocols is the application of
QDs to tracking and homing in whole animal
studies (see Lim et al., 2003; Ballou et al.,
2004; Kim et al., 2004; Smith et al., 2006). A
number of recent reviews refer to uses of QDs
in imaging, flow cytometry, and immunoas-
says (Bruchez and Hotz, 2006; Fu et al., 2005;
Michalet et al., 2005; Mulder et al., 2006;
Pinaud et al., 2006; Portney and Ozkan, 2006;
Prasad, 2006; Smith et al., 2006; Weng and
Ren, 2006).
Special characteristics and behaviors of QDs
One of the most powerful ways to deter-
mine local proximity of biologically relevant
molecules is through FRET (Fo¨rster resonance
energy transfer; UNITS 17.1 & 17.9) between a
donor and an acceptor fluorophore attached
to the two molecules of interest. In the case
of QDs, the large passivation and conjugation
shells surrounding the fluorescent core make
it difficult to use QDs for such measurements
since the efficiency of transfer varies inversely
with the 6th power of the distance between
donor and acceptor. Additionally, the broad
excitation spectrum of QDs prohibits their use
as FRET acceptors since it is not possible to
selectively excite the donor, resulting in a rela-
tively small enhancement of acceptor fluores-
cence due to FRET. An exception is the use of
a bioluminescent donor for QD-BRET as men-
tioned in the beginning of this unit (So et al.,
2006). QDs can act as donors in a FRET pair
when the acceptor lies in close proximity to
the passivation shell (see Lidke et al., 2005a;
Clapp et al., 2006; Pons et al., 2006). In this
case the QD should not have a large bio-shell
such as PEG conjugation.
Single QDs exhibit ‘blinking’ behavior or
intermittent fluorescence (see Fig. 25.1.4). Al-
though proper passivation of the semicon-
ductor core reduces blinking, it is generally
not possible to suppress this phenomenon
completely. The blinking follows an inverse
power law, as predicted for (1) an expo-
nential distribution of trap depths or (2) a
distribution of tunneling distances between
QD core/interface state (Kuno et al., 2000;
Shimizu et al., 2001). Hohng and Ha (2004)
were able to reduce blinking of single QDs
by treating them with high concentrations of
thiols, a procedure that is incompatible with
live-cell imaging. When tracking individual
QDs attached to cell surface receptors or the
cytoskeleton using high-speed acquisitions in
the 20 to 50 msec range, correction for the
blinking behavior must be made to avoid im-
proper segmentation of the loci or jumping of
the track between different QDs (Dahan et al.,
2003; Arndt-Jovin et al., 2006). However, this
blinking behavior can be used to advantage to
localize individual QDs with super resolution
(Lidke et al., 2005b; Hagen et al., 2007).
An advantageous property of QDs is the
CdSe electron dense core that can be detected
by transmission electron microscopy (Dahan
et al., 2003; Nisman et al., 2004). This makes
possible correlative dynamic fluorescence




The “tail wagging the dog” problem:
Quantum Dot size and valency
considerations
The size of a QD is comparable to that of an
antibody. Therefore, since the binding proper-
ties or biological activity of a ligand can be
influenced by its conjugation to a QD, careful
control experiments (such as flow cytometry
Nanotechnology
25.1.15
Current Protocols in Cell Biology Supplement 36
to characterize QD-ligand binding constants)
must be made to establish that there is no steric
influence of the QD.
QDs are multivalent, such that several lig-
ands can be coupled to each QD. This can
result in a single QDs binding multivalently to
multiple receptors (Cambi et al., 2007). The
researcher has to decide whether this is a con-
cern for his or her particular problem. If so, the
ligand should be coupled to the QD in a nearly
1:1 ratio (Lidke et al., 2004) and preblocking
of excess binding sites with free biotin may be
necessary (see Support Protocol 1).
Fixation
PFA (4%) is the preferred fixation solution
for samples labeled with QDs. The QD fluo-
rescence is destroyed by freezing or fixation in
−20◦C methanol. In addition, the use of vari-
ous mounting mediums must be tested to en-
sure that the medium does not degrade the QD
fluorescence. As QDs degrade, their emission
gradually shifts to lower wavelength and this
can be particularly precarious when several
spectrally distinct QDs are present. To avoid
such problems, store fixed samples in PBS at
4◦C, mount fixed samples in PBS, and image
within 24 hr of fixation.
Nonspecific binding
The authors recommend the PEG 2000-
coated QDs for most cellular applications
since they show reduced nonspecific binding
to cells and cell substrates, such as polylysine
or collagen. In addition, the presence of high
concentrations of BSA and the use of a higher
pH will help to reduce nonspecific binding.
The reader is reminded that stock solutions
of QDs are maintained by Invitrogen in 1 M
trimethylglycine at pH 8.5 and dilution into
buffers containing divalent cations will, over
time, result in aggregation and precipitation of
the QDs.
Controls
It is essential to prove that the QD signal
is reflective of the uncoupled ligand’s inter-
action with the receptor of interest and that
the QDs do not interfere, when appropriate,
with the ligand’s physiological activity. Con-
trols for such behavior include showing that
(1) unconjugated QDs do not bind to the cell
surface, (2) QD-ligands do not bind to cells not
expressing the membrane protein of interest,
(3) presaturation of the cell surface receptors
with unlabeled ligand blocks QD-ligand bind-
ing, and (4) addition of QD-ligand mimics un-
conjugated ligand. In addition, flow cytometry
(Basic Protocols 2 and 3) can be used to char-
acterize QD-ligand binding constants and cor-
relation with free ligand binding (Lidke et al.,
2004).
Other bioconjugation techniques
As described above, many types of QDs
with different bioconjugation are available.
In addition, manufacturers sell kits for alter-
native bio-coupling methods. See the man-
ufacturers’ Web sites for more information
(http://probes.invitrogen.com/p1roducts/qdotand
http://www.evidenttech.com). For a review of
other labeling methods see Smith et al. (2006).
Flow cytometric determination of binding
constants
Antibodies and ligands typically induce the
internalization of their receptor. In order to
prevent this from happening, both the cell sus-
pension and the ligand solutions have to be
kept on ice for the duration of the experiment.
If samples are not fixed before measurement,
internalization can take place in the instru-
ment as well. The sample can spend a signif-
icant amount of time at room temperature in
flow cytometers into which multiple samples
are loaded simultaneously (e.g., with a sample
loader or on a 96-well plate). In such cases,
the samples should be fixed before measure-
ment. Before fixation the unbound ligand has
to be removed by washing with excess PBS.
Dissociation of bound ligands starts immedi-
ately after the ligand concentration drops in the
medium. Therefore, washing can introduce er-
rors into the measurement. Consequently, it is
best to use flow cytometers into which sin-
gle tubes are loaded one-by-one, and use un-
fixed cells without washing. This can be done
since most flow cytometers are equipped with
a constant background subtraction algorithm,
therefore the contribution of extracellular flu-
orescence is reliably removed.
The authors strongly advise against using
the Scatchard analysis, i.e., a plot of the ratio
of bound ligand concentration to free ligand
concentration as a function of bound ligand
concentration, for fitting. In flow cytometric
experiments the measured fluorescence inten-
sities can be used instead of the bound lig-
and concentration. Before nonlinear regres-
sion programs became widely available, sci-
entists transformed data to make linear plots.
If the Scatchard plot can be fitted with a single
line, the x intercept and the slope of the line
correspond to the maximum number of bind-
ing sites (maximum fluorescence intensity)
and the negative reciprocal value of the Kd, re-
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plot reveals potentially important information
about the nature of binding (positive or nega-
tive cooperativity in the case of concave down
and concave up Scatchard plots, respectively),
the fitting results will be distorted due to er-
ror propagation inherent in the transformation
leading to the Scatchard plot.
If the fluorescence intensity does not sat-
urate, the following possibilities have to be
investigated:
1. Nonspecific binding: nonspecific bind-
ing sites are usually very difficult to saturate.
Dead cells may have significant non-specific
binding.
2. Ligand depletion: in most analyses it is
assumed that the amount of bound ligand is
negligible compared to the total amount avail-
able. If the number of binding sites is high, this
assumption does not hold, and the free ligand
concentration can be significantly lower than
the total (ligand depletion). In such a case sat-
uration of binding takes place at a much higher
total ligand concentration than without ligand
depletion. The ligand can also bind to the wall
of the flow cytometric tube leading to a similar
phenomenon.
3. Ligand binding can be compromised by
coupling to QD.
Flow cytometric determination of the
number of antibody binding sites
In the Quantum Simply Cellular kit the
same primary antibody is used for labeling the
beads and the cells whereas the Qifikit beads
are coated with a mouse monoclonal antibody.
Since secondary antibodies may show slight
variation with regard to binding to primary
antibodies, there is some advantage to the
Quantum Simply Cellular in that the secondary
antibody binds to the same primary antibody
on both cells and beads. In most cases (espe-
cially if the same isotype is used for labeling
the cells and coating the bead), this is unlikely
to be a major source of error. On the other
hand, the primary antibody is captured by its
Fc domain by the Quantum Simply Cellular
beads, a different orientation from when the
Fab domain binds to its epitope. It is unknown
to us whether the different orientation of the
primary antibodies has any influence on the
binding of the secondary antibody.
If the calibration line is prepared using the
background-corrected fluorescence intensities
of the calibration beads (as described in the
above protocols), the calibration line should
cross the origin of the plot, or have a y intercept
very close to zero. The calibration curve is
expected to be strictly linear, i.e., a correlation
coefficient of >0.98 and no splaying at high
concentrations. If the curve is nonlinear or it
does not cross the y axis at zero, nonspecific
binding of the antibody or incomplete labeling
of the beads may have happened. Check the
quality of the antibodies used and whether the
beads were mixed regularly during labeling.
If the fluorescence intensity of the cells is
higher than that of the brightest bead popula-
tion, the calibration line can be extrapolated.
But it has to be kept in mind that at very high
densities antibody binding may not be strictly
proportional to the number of antibody bind-
ing sites. Although the number of antibody
binding sites on the different bead population
may show batch-to-batch variation, the range
of the Qifikit beads usually extends higher
(∼5 × 105) than that of the Quantum Simply
Cellular beads (∼2 × 105).
Anticipated Results
Support Protocols 1 and 2: Collection of
eluted fractions from the size exclusion col-
umn or recovery of the QD fraction after fil-
tration should result in a purified QD-ligand
complex. The presence of QDs can be con-
firmed by recording an absorbance or emis-
sion spectrum. Concentration of QDs can be
calculated from the peak absorbance value if
one knows the extinction coefficient (available
from the manufacturer) for that particular QD.
Basic Protocol 1: During the imaging times
series, the researcher should observe a strong
QD signal localized at the position of the re-
ceptor (either on the membrane or internalized
in vesicles). Addition of unlabeled QDs should
not result in QD binding to the cell surface.
Large aggregates should not be seen in the
images—this would indicate cross-linking of
the QDs by ligand and the complex formation
conditions should be adjusted as discussed in
the Alternate Protocol.
For all of the basic protocols, detection lim-
its depend on the imaging conditions. Under
the right conditions and with sensitive emCCD
cameras one can detect single QD binding as
indicated in the Background Information sec-
tion and literature cited therein. It is difficult to
detect single QDs in raster scanning confocal
microscopes in live samples, but possible in
fixed material with long pixel dwell times and
line averaging.
Time Considerations
Support Protocol 1. Preparation and mix-
ing of reagents to form QD-ligand complexes
should take 15 to 20 min. Complexes should
incubate for at least 30 min. The time for
Nanotechnology
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purification depends on whether spin columns,
filters, or gravity columns are used, between
30 min to 2 hr is usual.
Basic Protocol 1. Replating of cells into
imaging chambers takes ∼30 min. The time
for an imaging experiment is dependent on
the processes being observed and the length
of the time series acquired. Quantitative im-
age analyses of image time series can be run
as batch jobs once the conditions of the ex-
periments have been standardized and macros
or plug-ins to the basic image processing soft-
ware have been concatenated. Tracking of in-
dividual QDs must normally be controlled by
operator intervention to avoid analysis of false
traces.
Basic Protocols 2 and 3. The labeling and
the flow cytometric experiment can be carried
out in ∼2 hr and analysis typically takes ∼1 hr.
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